Price
$4.00
Decreased by -4.08%
Dollar volume (20D)
3.97 M
ADR%
6.31
Earnings report date
Jun 18, 2024
Shares float
82.05 M
Shares short
21.29 M [25.95%]
Shares outstanding
84.64 M
Market cap
380.89 M
Beta
0.66
Price/earnings
N/A
20D range
3.41 4.67
50D range
3.25 5.29
200D range
3.25 10.45

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.

Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease.

Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.

The company was incorporated in 2004 and is headquartered in New York, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jun 18, 24 -0.13
Increased by +23.53%
-0.11
Decreased by -18.18%
Feb 7, 24 -0.11
Increased by +35.29%
-0.14
Increased by +21.43%
Nov 27, 23 -0.12
Increased by +33.33%
-0.15
Increased by +20.00%
Aug 8, 23 -0.14
Increased by +12.50%
-0.17
Increased by +17.65%
May 9, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
Feb 7, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
Nov 28, 22 -0.18
Decreased by -20.00%
-0.16
Decreased by -12.50%
Aug 9, 22 -0.16
Decreased by -14.29%
-0.15
Decreased by -6.67%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 N/A
Decreased by N/A%
-10.55 M
Increased by +19.54%
- -
Dec 31, 23 0.00
Decreased by N/A%
-8.62 M
Increased by +33.53%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-10.15 M
Increased by +29.00%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-11.28 M
Increased by +8.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-13.11 M
Decreased by -25.57%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-12.97 M
Decreased by -19.20%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-14.29 M
Decreased by -21.95%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-12.37 M
Decreased by -21.48%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY